# NeurAxis, Inc.

Type: Company (NRXS)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/neuraxis-inc
Canonical HTML page: https://getfinancebrief.com/entity/neuraxis-inc

## Recent coverage (1 stories)

### Relmada and NeurAxis Q4 2025: Clinical Milestones and Commercial Scaling
2026-03-20 14:56:09 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting critical pivots in clinical development and commercial execution. Relmada remains focused on its Phase 3 REL-1017 program for depression, while NeurAxis reports steady growth in its neuromodulation therapy for pediatric patients.
Full story: https://getfinancebrief.com/story/relmada-neuraxis-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.